An announcement from RedHill Biopharma ( (RDHL) ) is now available.
RedHill Biopharma Ltd. has announced its Annual General Meeting of Shareholders scheduled for May 5, 2025, in Tel Aviv, Israel. Key agenda items include the appointment of auditors, re-election of board members, approval of an amended compensation policy, and grants of restricted share units to executives and directors. The meeting will also address an increase in the company’s authorized share capital, with shareholders having the opportunity to review the financial statements for the fiscal year ended December 31, 2024. The outcomes of this meeting could impact the company’s governance and financial strategies moving forward.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a biopharmaceutical company based in Tel Aviv, Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases and cancer.
YTD Price Performance: -56.25%
Average Trading Volume: 92,333
Technical Sentiment Signal: Buy
Current Market Cap: $3.73M
For detailed information about RDHL stock, go to TipRanks’ Stock Analysis page.